Brief: Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
02/12/2024 13:40
Dec 2 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS ANNOUNCES FDA CLEARANCE OF IND APPLICATION
FOR
PHASE 2 CLINICAL TRIAL OF HEPZATO™ IN LIVER-DOMINANT METASTATIC
COLORECTAL CANCER
* DELCATH SYSTEMS INC - PRIMARY ENDPOINT DATA EXPECTED BY
END OF
2027
* DELCATH SYSTEMS INC: OVERALL SURVIVAL, SECONDARY ENDPOINT,
IS
EXPECTED IN 2028
Source text: ID:nBw4PjpXa
Further company coverage: DCTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview